Download PDF
Thromb Haemost 1994; 72(03): 434-437
DOI: 10.1055/s-0038-1648885
Original Article
Schattauer GmbH Stuttgart

Relation between Plasminogen Activator Inhibitor-1 and Hepatic Enzyme Concentrations in Hyperlipidemic Patients

E Bruckert
1   The Service d’endocrinologie-métabolisme, Hôpital Pitié Salpétrière, Paris, France
,
A Ankri
2   Service d’hématologie, Hôpital Pitié Salpétrière, Paris, France
,
P Glral
1   The Service d’endocrinologie-métabolisme, Hôpital Pitié Salpétrière, Paris, France
,
G Turpin
1   The Service d’endocrinologie-métabolisme, Hôpital Pitié Salpétrière, Paris, France
› Author Affiliations
Further Information

Publication History

Received 09 December 1993

Accepted after resubmission 10 May 1994

Publication Date:
25 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Plasminogen activator inhibitor type-1 (PAI-1) is a key determinant of the fibrinolytic capacity. Its activity correlates with most of the characteristic features of insulin resistance syndrome, i. e. obesity, high blood pressure and hyperlipidemia.

We measured plasma PAI-1 antigen levels in 131 asymptomatic men (aged 44.2 ± 11 years) who had been referred for hyperlipidemia. Those taking medication and those with a secondary hyperlipidemia were excluded.

We confirmed the correlation between PAI-1 levels and the following variables: body mass index, blood pressure, triglyceride concentration, and blood glucose and insulin levels before and after an oral glucose tolerance test. We also found a significant and independent correlation between PAI-1 and the concentration of the hepatic enzymes glutamyl transferase, alanine aminotransferase and aspartate aminotransferase.

Mild liver abnormalities (presumably steatosis) may thus be one of the factors accounting for high plasma PAI-1 levels in hyperlipidemic patients.

 

  • References

  • 1 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
    PubMedGoogle Scholar
  • 2 Oseroff A, Krishnamourti C, Hasset A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989; 113: 88-93
    PubMedGoogle Scholar
  • 3 Hamsten A, Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blom-backe M, Wiman B. Plasminogen activator inhibitors in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-8
    PubMedGoogle Scholar
  • 4 Erickson LA, Fici GH, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-76
    CrossrefPubMedGoogle Scholar
  • 5 Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationships between plasma insulin triglyceride, Body Mass Index, and plasminogen activator inhibitor 1. Diabete et Metabolisme 1987; 13: 331-336
    PubMedGoogle Scholar
  • 6 Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA. Levels of three haemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator and type-1 plasminogen activator inhibitor Arteriosclerosis 1989; 9: 934-939
    PubMedGoogle Scholar
  • 7 Metha J, Metha P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-268
    CrossrefPubMedGoogle Scholar
  • 8 Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 1989; 38(9): 913-915
    CrossrefPubMedGoogle Scholar
  • 9 Landin K, Tengbom L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. Journal of Internal Medicine 1990; 22: 273-278
    PubMedGoogle Scholar
  • 10 Cucuianu M, Zdrenghea D, Pop M, Opincaru A. Increased serum gamma-glutamyl transferase in hypertriglyceridemia: comparison with serum pseudocholine esterase. Clin Chim Acta 1976; 71: 419-427
    CrossrefPubMedGoogle Scholar
  • 11 Simpson HCR, Mann JL Meade TW, Chakrabarti R, Stirling Y, Woolf L. Hypertriglyceridemia and hypercoagulability. Lancet 1983; 1: 786-790
    PubMedGoogle Scholar
  • 12 Assman G, Brewer Jr HB. Genetic (primary) forms of hyperlipidemia. Am J Cardiol 1991; 68: 13A-16A
    CrossrefPubMedGoogle Scholar
  • 13 Bruckert E, Ankri A, Jung M, Turpin G, De Gennes JL. Mild liver abnormalities are associated with elevated plasma factor VII and protein C in hypertriglyceridemic patients. Eur J Med 1993; 8: 461-465
    PubMedGoogle Scholar
  • 14 Fruchart JC, Beucler I, Blaton V, Canal J, Douste-Blazy L, Gambert P, Ka-terman R, Legrand A, Polonowski J, Steinmetz J, Thouvenot JP. Methode selectionnee pour le dosage du cholesterol des lipoproteines non precipi-tables par le phospho-tungstate de sodium en presence de chlorure de magnesium. Inf Scient Biol 1982; 8: 69-72
    PubMedGoogle Scholar
  • 15 Mussoni L, Mannucci L, Sirtori M, Camera M, Madema P, Sironi L, Tre-moli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arteriosclerosis and Thrombosis 1992; 12: 19-27
    CrossrefPubMedGoogle Scholar
  • 16 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
    PubMedGoogle Scholar
  • 17 Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
    PubMedGoogle Scholar
  • 18 Bruckert E, Dairou F, De Gennes JL. Complications cardiovasculaires de rhypertriglyceridemie endogene mineure. Arch Mai Coeur 1987; 11: 1587-92
    PubMedGoogle Scholar
  • 19 Aberg H, Lithell H, Selinus I, Hedstrand J. Serum triglycerides as a risk factor for myocardial infarction but not angina pectoris. Results from a 10 years follow up of Uppsala primary preventive study. Atherosclerosis 1985; 54: 89-97
    PubMedGoogle Scholar
  • 20 Grant PJ, Kruithof EKO, Felley CP, Felber JP, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute inreases in plasminogen activator inhibitor 1 concentrations in man. Clin Sci 1990; 79: 513-516
    CrossrefPubMedGoogle Scholar
  • 21 Juhan-Vague I, Vague P. Hypofibrinolysis and insulin resistance. Diab Metab 1991; 17(Suppl 2): 96-100
    PubMedGoogle Scholar
  • 22 Latron Y, Chautan M, Anfosso F, Alessi G, Nalbone G, Lafont H, Juhan-Vagu I. Stimulating effect of oxidized low density lipoprotein on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arteriosclerosis and Thrombosis 1991; 11: 1821-1829
    CrossrefPubMedGoogle Scholar
  • 23 Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-1073
    CrossrefPubMedGoogle Scholar
  • 24 Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-825
    CrossrefPubMedGoogle Scholar
  • 25 Tran-Thang C, Fasel-Felley J, Pralong G, Hogfsetter JR, Bachmann F, Kruithof EKO. Plasminogen activator and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost 1989; 62 (02) 651-653
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 iest G, Henny J, Schiele F. References en biologie clinique. Elsevier editions scientifiques 1990; 275-293
    PubMedGoogle Scholar
  • 27 Braillon A, Capron JP. Foie et obesite. Gastroenterol Clin Biol 1983; 7: 627-34
    PubMedGoogle Scholar